NewAmsterdam Financial Statements From 2010 to 2024

Stocks . USA . 
Stock . NewAmsterdam Pharma
NAMS Stock   20.80  0.04  0.19%   
NewAmsterdam Pharma financial statements provide useful quarterly and yearly information to potential NewAmsterdam Pharma investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on NewAmsterdam Pharma financial statements helps investors assess NewAmsterdam Pharma's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting NewAmsterdam Pharma's valuation are summarized below:
Market Capitalization
2.3 B
Enterprise Value Revenue
44.6331
Revenue
33.6 M
Earnings Share
(2.21)
Quarterly Revenue Growth
8.898
There are over ninety-seven available fundamental ratios for NewAmsterdam Pharma, which can be analyzed over time and compared to other ratios. All traders should check NewAmsterdam Pharma's last-minute fundamentals against the performance from 2010 to 2024 and make sure the trends continue to evolve in the right direction. Market Cap is likely to gain to about 871.8 M in 2024. Enterprise Value is likely to gain to about 514.4 M in 2024

NewAmsterdam Pharma Total Revenue

12.12 Million

Check NewAmsterdam Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among NewAmsterdam Pharma's main balance sheet or income statement drivers, such as Tax Provision of 28.4 K, Net Interest Income of 3.6 M or Interest Income of 11.8 M, as well as many indicators such as Price To Sales Ratio of 68.31, Dividend Yield of 0.0 or PTB Ratio of 3.02. NewAmsterdam financial statements analysis is a perfect complement when working with NewAmsterdam Pharma Valuation or Volatility modules.
  
Check out the analysis of NewAmsterdam Pharma Correlation against competitors.
For more information on how to buy NewAmsterdam Stock please use our How to Invest in NewAmsterdam Pharma guide.

NewAmsterdam Pharma Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets260.6 M347.1 M86.7 M
Slightly volatile
Short and Long Term Debt Total57 K60 K8.6 M
Slightly volatile
Other Current Liabilities25.2 M24 M4.5 M
Slightly volatile
Total Current Liabilities29.7 M49.9 M17.7 M
Slightly volatile
Property Plant And Equipment Net122.9 K101 K46 K
Slightly volatile
Accounts Payable10 M16.9 M3.4 M
Slightly volatile
Cash231 M340.4 M76.6 M
Slightly volatile
Non Current Assets Total290.7 K306 K5.7 M
Slightly volatile
Cash And Short Term Investments231 M340.4 M76.6 M
Slightly volatile
Common Stock Shares Outstanding86.3 M82.2 M26.7 M
Slightly volatile
Liabilities And Stockholders Equity260.6 M347.1 M86.7 M
Slightly volatile
Non Current Liabilities Total8.4 M8.8 M9.2 M
Slightly volatile
Other Current Assets6 M4.5 M3 M
Slightly volatile
Total Liabilities35.4 M58.7 M19.5 M
Slightly volatile
Net Invested Capital228.5 M288.4 M76 M
Slightly volatile
Property Plant And Equipment Gross147.7 K101 K54.3 K
Slightly volatile
Short and Long Term Debt9.3 M10.5 M11.4 M
Slightly volatile
Total Current Assets237.3 M346.8 M79.5 M
Slightly volatile
Capital Stock9.7 M10.2 M48.7 M
Slightly volatile
Short Term Debt57 K60 K8.6 M
Slightly volatile
Common Stock9.7 M10.2 M48.7 M
Slightly volatile
Property Plant Equipment111.1 K218.5 K56.1 K
Slightly volatile
Current Deferred Revenue9.4 M8.9 M5 M
Slightly volatile
Other Assets23.9 K25.1 K579.5 K
Slightly volatile
Net Receivables2.3 M1.7 M4.3 M
Slightly volatile
Other Stockholder Equity713.4 M679.4 M132.7 M
Slightly volatile
Accumulated Other Comprehensive Income3.6 M4.4 M1.3 M
Slightly volatile
Good Will186.5 K209.8 K228.4 K
Slightly volatile
Intangible Assets161.5 K170 K71.9 M
Slightly volatile

NewAmsterdam Pharma Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization51.5 K49 K8.3 K
Slightly volatile
Interest Expense7.1 M6.8 M1.2 M
Slightly volatile
Selling General Administrative13.5 M25.7 M5.1 M
Slightly volatile
Selling And Marketing Expenses4.3 M4.1 M726 K
Slightly volatile
Other Operating Expenses94 M183.2 M32.7 M
Slightly volatile
Research Development167.4 M159.4 M31.9 M
Slightly volatile
Total Operating Expenses206.9 M197.1 M41.1 M
Slightly volatile
Reconciled Depreciation37.4 K49 K12.2 K
Slightly volatile
Income Tax Expense25.6 K27 K5 M
Slightly volatile
Cost Of Revenue47.5 K44.4 K22.5 K
Slightly volatile

NewAmsterdam Pharma Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow491.1 M467.7 M69.8 M
Slightly volatile
Depreciation37.4 K49 K12.2 K
Slightly volatile
Capital Expenditures19.2 K24 K14.6 K
Slightly volatile
Total Cash From Financing Activities8.5 M8.9 M39.1 M
Slightly volatile
End Period Cash Flow231 M340.4 M76.6 M
Slightly volatile
Change To Liabilities5 M9.5 M2.7 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio68.3165.054110.6356
Slightly volatile
Days Sales Outstanding6.37.097.7203
Slightly volatile
Stock Based Compensation To Revenue0.03430.03860.0421
Slightly volatile
Capex To Depreciation0.20.211.1822
Slightly volatile
Sales General And Administrative To Revenue1.611.811.9742
Slightly volatile
Research And Ddevelopement To Revenue13.1212.49142.4395
Slightly volatile
Capex To Revenue0.0020.00194.0E-4
Slightly volatile
Cash Per Share6.144.14372.7511
Slightly volatile
Intangibles To Total Assets5.0E-45.0E-40.1356
Slightly volatile
Current Ratio5.266.95012.5816
Slightly volatile
Receivables Turnover37.0641.745.4045
Slightly volatile
Graham Number10.213.04164.8871
Slightly volatile
Capex Per Share3.0E-43.0E-47.0E-4
Slightly volatile
Revenue Per Share0.150.15534.4028
Slightly volatile
Interest Debt Per Share0.09040.09520.5047
Slightly volatile
Debt To Assets1.011.141.2371
Slightly volatile
Ebt Per Ebit1.920.96691.4729
Slightly volatile
Total Debt To Capitalization1.151.31.414
Slightly volatile
Quick Ratio5.266.95012.5816
Slightly volatile
Net Income Per E B T0.880.991.0816
Slightly volatile
Cash Ratio5.036.82312.423
Slightly volatile
Days Of Sales Outstanding6.37.097.7203
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.11.00021.0082
Slightly volatile
Fixed Asset Turnover120126594
Slightly volatile
Debt Ratio1.011.141.2371
Slightly volatile
Price Sales Ratio68.3165.054110.6356
Slightly volatile
Asset Turnover0.03490.03680.1611
Slightly volatile

NewAmsterdam Pharma Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap871.8 M830.3 M249.5 M
Slightly volatile

NewAmsterdam Fundamental Market Drivers

Cash And Short Term Investments340.4 M

NewAmsterdam Upcoming Events

29th of March 2024
Upcoming Quarterly Report
View
31st of December 2023
Next Fiscal Quarter End
View
29th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About NewAmsterdam Pharma Financial Statements

NewAmsterdam Pharma shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although NewAmsterdam Pharma investors may analyze each financial statement separately, they are all interrelated. The changes in NewAmsterdam Pharma's assets and liabilities, for example, are also reflected in the revenues and expenses on on NewAmsterdam Pharma's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue8.9 M9.4 M
Total Revenue12.8 M12.1 M
Cost Of Revenue44.4 K47.5 K
Stock Based Compensation To Revenue 0.04  0.03 
Sales General And Administrative To Revenue 1.81  1.61 
Research And Ddevelopement To Revenue 12.49  13.12 
Revenue Per Share 0.16  0.15 
Ebit Per Revenue(12.99)(13.63)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for NewAmsterdam Stock Analysis

When running NewAmsterdam Pharma's price analysis, check to measure NewAmsterdam Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NewAmsterdam Pharma is operating at the current time. Most of NewAmsterdam Pharma's value examination focuses on studying past and present price action to predict the probability of NewAmsterdam Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NewAmsterdam Pharma's price. Additionally, you may evaluate how the addition of NewAmsterdam Pharma to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY